NCT06072118已完成2 期
A Multicenter, Single-arm, Clinical Trial of Adrenomedullin for Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
National Cerebral and Cardiovascular Center, Japan1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年1月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Cerebral blood flow change rate evaluated by arterial spin labeling
研究概览
简要总结
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common form of hereditary cerebral small vessel disease, with no proven disease-modifying treatments. Adrenomedullin, a vasoactive peptide, has angiogenic, vasodilation, anti-inflammatory, and anti-oxidative properties and could have triple sites of action on components of the neuro-glial-vascular unit consisting of vessels, microglia and oligodendrocytes or, more specifically, on the white matter oligovascular unit. The aim of the AMCAD trial is to assess the safety and efficacy of Adrenomedullin in CADASIL patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have given written informed consent from the patient or the sponsor to participate in the clinical trial
- •Patients aged between 20 and 90 at the time of obtaining consent
- •Patients diagnosed as CADASIL after confirming NOTCH3 gene mutation by genetic testing
- •Patients with Mini-mental state examination-J score of 10-27 or Trail maiking test score (age ajustment) of average + 1.5 SD (standard deviation) or higher
排除标准
- •Patients who cannot perform cognitive function tests (deafness, blindness, etc., MMSE-J less than 10 points Severe cognitive impairment, etc.)
- •Patients received reatment with prohibited drugs or prohibited therapy within the past 12 weeks from the time of registration
- •Patients who started to take concomitant restriction drugs or changed dosage of concomitant restriction drugs within the past 4 weeks from the time of registration
- •Patients whose Mini-mental state examination-J with 4 or more points improvements between the time of registration and 4 weeks or more at the time of screening (If patients who take concomitant restriction drugs)
- •Patients with active infections requiring antibiotic treatment at registration
- •Patients with a disability equivalent to modified Rankin Scale 5 at registration
- •Patients with severe consciousness impairment (Japan Coma Scale 100 or more)
- •Patients with severe renal impairment (estimated GFR less than 30 mL / min / 1.73m2) at registration
- •Patients with severe liver damage (transaminase AST (GOT) or ALT (GPT) 100 IU / L or more) at registration
- •Patients diagnosed as having cerebral infarction or intracranial hemorrhage or transient ischemic attack or cerebral aneurysm with high probability of rupture within the last 12 weeks from the time of registration
- •Patients with occlusion or severe stenosis of the intracranial main artery or carotid artery at the time of registration
- •Patients with significant ECG abnormalities (atrioventricular block of 2-3 degrees, extension of QRS interval of 120 ms or more, extension of QTcB of 450 msec or more) at registration, or past histroy of acute coronary syndrome or acute heart failure within the last 12 weeks from the time of registration
- •Patients with systolic blood pressure less than 100 mmHg at registration
- •Patients whose pulse rate is less than 45 beats / minute or 120 beats / minute or more at registration
- •Patients with substance abuse or alcoholism
- •Patients who cannot perform MRI
- •Patients with active solid malignant tumors
- •Patients who do not give consent to contraception from the date of obtaining consent until the end of the safety evaluation period
- •Pregnant, lactating, and possibly pregnant
- •Patient who participated in another trial within 24 weeks before registration
- •Other patients judged by the Investigator or Investigator to be ineligible for this study
研究组 & 干预措施
Adrenomedullin group
Experimental
干预措施: Adrenomedullin (Drug)
结局指标
主要结局
Cerebral blood flow change rate evaluated by arterial spin labeling
时间窗: at 28 days post adrenomedullin administration
Frontal lobe
次要结局
- Change in times of Trail making test-A/B from baseline evaluation(at 15 days / 28 days / 90 days / 180 days post adrenomedullin administration)
- Safety: Serious adverse event(From the initiation of adrenomedullin administration to 28 days post)
- Change in scores of Montreal cognitive assessment from baseline evaluation(at 15 days / 28 days / 90 days / 180 days post adrenomedullin administration)
- Cerebral blood flow change rate evaluated by single photon emission computed tomography(at 28 days post adrenomedullin administration)
- Cerebral blood flow change rate evaluated by arterial spin labeling(at 8 hours / 15 days / 28 days / 90 days / 180 days post adrenomedullin administration)
- Fractional anisotropy change rate of the white matter evaluated by MR diffusion tensor imaging(at 8 hours / 15 days / 28 days / 90 days / 180 days post adrenomedullin administration)
- Occurence of cerebral infarction(at 8 hours / 15 days / 28 days / 90 days / 180 days post adrenomedullin administration)
- Mean diffusivity change rate of the white matter evaluated by MR diffusion tensor imaging(at 8 hours / 15 days / 28 days / 90 days / 180 days post adrenomedullin administration)
- Change in scores of Wechsler Adult Intelligence Scale-Fourth edition from baseline evaluation(at 15 days / 28 days / 90 days / 180 days post adrenomedullin administration)
研究者
Masafumi Ihara
Director of Neurology, National Cerebral and Cardiovascular Center
National Cerebral and Cardiovascular Center, Japan
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Natural History Study of CADASILArterial StiffnessGermline Mutation in the NOTCH 3 GenePathogenesis of CADASILClinical Phenotype of CADASILCardiovascular DiseaseNCT05072483National Heart, Lung, and Blood Institute (NHLBI)155
已完成
不适用
CADASIL Disease DiscoveryGermline Mutation in the NOTCH 3 GeneArterial StiffnessPathogenesis of CADASILClinical Phenotype of CADASILCardiovascular DiseaseNCT02821780National Heart, Lung, and Blood Institute (NHLBI)20
已完成
不适用
Generation of a Cellular Model of CADASIL From Skin FibroblastsCADASILNCT02032225Institut National de la Santé Et de la Recherche Médicale, France8
已完成
2 期
Efficacy and Safety of Tocotrienols in CADASILCadasilNCT04658823Hovid Berhad50
招募中
不适用
CADASIL Registry StudyCadasilNCT04310098Bin Cai1,000